SION - CIK 0002036042
The table below shows Sionna Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $18.96M | $16.04M | $15.38M | $13.67M | $24.58M | $8.23M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.64M |
| $7.76M |
| $6.52M |
| $5.99M |
| $3.40M |
| $3.06M |
| Operating income | -$29.60M | -$23.80M | -$21.91M | -$19.66M | -$27.98M | -$11.29M |
| Income tax | - | - | - | - | - | - |
| Net income | -$26.78M | -$20.28M | -$18.07M | -$16.48M | -$25.44M | -$8.55M |
| EPS (diluted) | -$0.60 | -$0.46 | -$410.00 | -$0.62 | -$5.67 | -$2.71K |